| Schedule of continued operations by reportable segment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
($in thousands) |
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Three Months Ended June 30, 2020 |
|
Sales |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
9,415 |
|
$ |
42 |
|
$ |
9,457 |
Direct cost of goods |
|
|
(3,124) |
|
|
— |
|
|
(3,124) |
Sales and marketing costs |
|
|
(3,400) |
|
|
— |
|
|
(3,400) |
Research and development |
|
|
— |
|
|
(17,273) |
|
|
(17,273) |
General and administrative |
|
|
(1,349) |
|
|
(9,707) |
|
|
(11,056) |
Other expense |
|
|
(172) |
|
|
(2,895) |
|
|
(3,067) |
Segment income (loss) |
|
$ |
1,370 |
|
|
(29,833) |
|
$ |
(28,463) |
Segment assets |
|
|
|
|
|
|
|
|
|
Intangible assets, net |
|
|
6,667 |
|
|
— |
|
|
6,667 |
Tangible assets |
|
|
19,133 |
|
|
242,773 |
|
|
261,906 |
Total segment assets |
|
$ |
25,800 |
|
$ |
242,773 |
|
$ |
268,573 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
($ in thousands) |
|
Products |
|
Product |
|
|
|
Three Months Ended June 30, 2019 |
|
Sales |
|
Development |
|
Consolidated |
Net Revenue |
|
$ |
8,199 |
|
$ |
1,051 |
|
$ |
9,250 |
Direct cost of goods |
|
|
(2,386) |
|
|
— |
|
|
(2,386) |
Sales and marketing costs |
|
|
(4,202) |
|
|
— |
|
|
(4,202) |
Research and development(1) |
|
|
— |
|
|
(18,711) |
|
|
(18,711) |
General and administrative |
|
|
(747) |
|
|
(8,494) |
|
|
(9,241) |
Other expense |
|
|
— |
|
|
(2,190) |
|
|
(2,190) |
Segment income (loss) |
|
$ |
864 |
|
$ |
(28,344) |
|
$ |
(27,480) |
Segment assets |
|
|
|
|
|
|
|
|
|
Intangible assets, net |
|
|
971 |
|
|
— |
|
|
971 |
Tangible assets |
|
|
8,342 |
|
|
217,951 |
|
|
226,293 |
Total segment assets |
|
$ |
9,313 |
|
$ |
217,951 |
|
$ |
227,264 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
($in thousands) |
|
Products |
|
Product |
|
|
|
Six Months Ended June 30, 2020 |
|
Sales |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
21,361 |
|
$ |
1,014 |
|
$ |
22,375 |
Direct cost of goods |
|
|
(6,934) |
|
|
— |
|
|
(6,934) |
Sales and marketing costs |
|
|
(8,079) |
|
|
— |
|
|
(8,079) |
Research and development |
|
|
— |
|
|
(32,390) |
|
|
(32,390) |
General and administrative |
|
|
(2,302) |
|
|
(19,594) |
|
|
(21,896) |
Other expense |
|
|
(379) |
|
|
(5,228) |
|
|
(5,607) |
Segment income (loss) |
|
$ |
3,667 |
|
|
(56,198) |
|
$ |
(52,531) |
Segment assets |
|
|
|
|
|
|
|
|
|
Intangible assets, net |
|
|
6,667 |
|
|
— |
|
|
6,667 |
Tangible assets |
|
|
19,133 |
|
|
242,773 |
|
|
261,906 |
Total segment assets |
|
$ |
25,800 |
|
$ |
242,773 |
|
$ |
268,573 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
($in thousands) |
|
Products |
|
Product |
|
|
|
Six Months Ended June 30, 2019 |
|
Sales |
|
Development |
|
Consolidated |
Net Revenue |
|
$ |
14,324 |
|
$ |
1,403 |
|
$ |
15,727 |
Direct cost of goods |
|
|
(4,270) |
|
|
— |
|
|
(4,270) |
Sales and marketing costs |
|
|
(7,695) |
|
|
— |
|
|
(7,695) |
Research and development |
|
|
— |
|
|
(42,434) |
|
|
(42,434) |
General and administrative |
|
|
(1,139) |
|
|
(18,087) |
|
|
(19,226) |
Other expense |
|
|
— |
|
|
14,163 |
|
|
14,163 |
Segment income (loss) |
|
$ |
1,220 |
|
$ |
(44,955) |
|
$ |
(43,735) |
Segment assets |
|
|
|
|
|
|
|
|
|
Intangible assets, net |
|
|
971 |
|
|
— |
|
|
971 |
Tangible assets |
|
|
8,342 |
|
|
217,951 |
|
|
226,293 |
Total segment assets |
|
$ |
9,313 |
|
$ |
217,951 |
|
$ |
227,264 |
|